Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company,  announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative plasma-derived therapy formulations for the treatment of rare conditions.

Following the completion of in vitro proof of concept studies of a novel plasma-derived therapy formulation, Nanoform will provide non-GMP nanomaterial to Takeda for in vivo studies. The first results of these studies are expected by early 2025.

"Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market," commented Dr. Edward Haeggström, CEO of Nanoform. "We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship."

The value of this pre-clinical (non-GMP) project is in line with Nanoform's guided business model of €0.05m to €0.5m per non-GMP project. It is the intention of both Nanoform and Takeda to develop medicine candidates to clinic and then take them as products to the market.

Nanoform Biologics' nanoforming technology can deliver large-molecule drug particles of tuneable size and morphology, while retaining biological activity. The technology can be applied across the biologics field, from 1 to 150KDa, to enable novel routes of delivery, enhance drug loading, tailor release profiles and engineer new drug combinations.